Abeona Therapeutics (ABEO) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed X4 Pharmaceuticals (XFOR) over the past year, losing 3.2% versus a loss of 18.3%. Over five years, ABEO leads with a -77.7% price change compared with -98.2% for XFOR. Abeona Therapeutics is the larger company by market cap ($284.2 million vs $272.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | XFOR |
|---|---|---|
| Share price | $4.97 | $2.75 |
| Market cap | $284.20M | $272.16M |
| 1-day change | -2.17% | -2.31% |
| YTD return | -3.61% | -29.75% |
| 1-year return | -3.24% | -18.31% |
| 5-year return | -77.67% | -98.21% |
| P/E ratio (TTM) | — | 137.25 |
| EPS (TTM) | $-1.18 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $4.83 |
| 52-week low | $4.00 | $2.70 |
| Distance from 52-week high | -35.03% | -43.17% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +279.88% | +322.59% |
| Average volume | 1.41M | 843.50K |
| Shares outstanding | 57.18M | 99.15M |
| Employees | 226 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed XFOR by 15.1 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
ABEO vs XFOR FAQ
Which is bigger, Abeona Therapeutics or X4 Pharmaceuticals?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $284.20M compared with $272.16M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, ABEO or XFOR?
ABEO returned -3.24% over the past 12 months, compared with -18.31% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and X4 Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Abeona Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for X4 Pharmaceuticals.